Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?

Simply Wall St.10-08

Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading. Recent ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2673504724?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-08 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2673504724","market":"us","top_or_hot":-1,"title":"Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?","media":"Simply Wall St.","content":"<div>\n<p>Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading. Recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-08 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading. Recent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REZ","symbol_name":"住宅房产信托ETF-iShares","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi","article_id":"2673504724","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-following-its-350-mi","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2673504724","pubTimestamp":1791427550,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading.\nRecent trading shows that momentum in Spyre Therapeutics has cooled in the short term, with the 7 day share price return down 9.2%, the 30 day move lower by 9.1%, and the 90 day share price performance down 18.1%. This is occurring even though the year to date share price return is 164.4% and the 1 year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"REZ":"住宅房产信托ETF-iShares","BK4215":"住宅房地产投资信托","EQR":"Equity","BK4588":"碎股","SYRE":"SPYRE THERAPEUTICS INC","BK4585":"ETF&股票定投概念","LFSC":"F/m Emerald Life Sciences Innovation ETF","BK4139":"生物科技"},"translate_title":"Spyre Therapeutics (SYRE) 在筹集 3.5 亿美元股权后是否已全部定价？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFSC":0.6,"REZ":0.6,"SYRE":1.5,"EQR":1.5},"content_text":"Spyre Therapeutics (SYRE) has moved into focus after completing a US$350.0 million follow on equity offering at US$85 per share, adding 4,117,648 common shares at a discount to prior trading. Recent trading shows that momentum in Spyre Therapeutics has cooled in the short term, with the 7 day share price return down 9.2%, the 30 day move lower by 9.1%, and the 90 day share price performance down 18.1%. This is occurring even though the year to date share price return is 164.4% and the 1 year total shareholder return is very large at over 3.5x, pointing to a stock that has already rewarded early holders while more recent weakness reflects investors reassessing risk after the upsized equity raise and higher cash balance. Scan beyond Spyre Therapeutics and see how other biotechs are reacting to fresh capital raises and trial funding by reviewing the hand picked 20 high quality undiscovered gems. Spyre Therapeutics now has more cash and a bigger share count after the US$350.0 million offering, so is most of the upside already in the rear view mirror, or is investors’ optimism only partly priced in? AdvertisementMost Popular Narrative: 33% Undervalued Analysts following Spyre Therapeutics see a fair value meaningfully above the last close of $80.85, which puts a spotlight on how much of the story is tied to its antibody pipeline and long cash runway rather than current revenue or earnings.  The plan to use co formulated α4β7, TL1A and IL 23 antibodies with extended half life and high concentration formulations for less frequent subcutaneous dosing, if it translates into high uptake among IBD prescribers, could support premium pricing and help net margins over time.  See why 2 investors see Spyre Therapeutics as 33% undervalued. Result: Fair Value of $120.08 (UNDERVALUED) Still, the Spyre Therapeutics story could change quickly if TL1A data in newer autoimmune settings underwhelms or if further insider selling weighs on confidence. Find out about the key risks to this Spyre Therapeutics narrative. Next Steps With sentiment around Spyre Therapeutics clearly mixed, you may want to move quickly and weigh both sides of the story by reviewing the 1 key reward and 5 important warning signs in the 1 key reward and 5 important warning signs. Looking for more investment ideas beyond Spyre Therapeutics? If Spyre Therapeutics has your attention, do not stop here. Use the Simply Wall St Screener to compare fresh ideas and pressure test your next move.  Target resilient balance sheets by scanning companies in the list of solid balance sheet and fundamentals (25 results) and see which businesses pair financial strength with room for upside. Hunt for potential mispricings using the 29 high quality undervalued stocks and quickly spot stocks where quality and valuation look out of sync. Stack your watchlist with differentiated ideas through the 12 elite penny stocks with strong financials before the crowd starts paying attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2673504724","isCrawlerRequest":true}